Latest news
Cartesian Therapeutics reports Q2 2026: $149.3M cash; net income $15.8M; Phase 3 MG data expected 1Q27 - TradingViewTradingView · Thu, 06 Aug 2026 11:13:01 GMTDyne Therapeutics reports Q2 net loss $178.6M, cash $898.5M; BLA for z-rostudirsen accepted with PDUFA Jan 21, 2027 - TradingViewTradingView · Wed, 29 Jul 2026 20:43:04 GMTSpruce Biosciences Appoints Dr. Adrian Quartel as Chief Medical Officer Ahead of Planned BLA Filing - citybizcitybiz · Mon, 27 Jul 2026 14:21:34 GMT